🇺🇸 FDA
Pipeline program

ARI-0001, YESCARTA 0.4 – 2 x 10e8 cells dispersion for infusion

HO161

Phase 2 small_molecule active

Quick answer

ARI-0001, YESCARTA 0.4 – 2 x 10e8 cells dispersion for infusion for relapsed/refractory Non-Hodgkin Lymphoma is a Phase 2 program (small_molecule) at Disc Medicine with 1 ClinicalTrials.gov record(s).

Program details

Company
Disc Medicine
Indication
relapsed/refractory Non-Hodgkin Lymphoma
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials